Agency / Source: Neuronix Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System - Neuronix Ltd announced today the first group of mild to moderate Alzheimer patients to be successfully treated by the neuroAD™ Therapy System in London - NeuronixMedical.com
Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System

 

PRZOOM - /newswire/ - Yoqneam, Israel, 2017/07/18 - Neuronix Ltd announced today the first group of mild to moderate Alzheimer patients to be successfully treated by the neuroAD™ Therapy System in London - NeuronixMedical.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

“It’s made me want to live, it’s changed my life” First Alzheimer’s disease patients successfully treated by novel technology in London;

The Neuronix neuroAD™ Therapy System is the first medical device that is CE-approved, for the treatment of mild to moderate Alzheimer’s disease. Its unique and patent protected technology combines transcranial magnetic stimulation (TMS) to those brain regions affected by Alzheimer’s disease, with concurrently delivered computerized cognitive training targeting the same affected regions.
In several double-blind placebo controlled clinical studies, including recently completed phase-III multi-center US study, it was shown that following 6 weeks of daily 1-hour sessions, patients experienced clinically and statistically significant improvement in their cognitive functioning and other reported behavioural measures.
Neuronix established its London Center, at 29 Weymouth Street, London, W1, earlier this year, to offer the neuroAD™ Therapy System treatment to patients with established mild to moderate Alzheimer’s disease. To date 16 patients have been treated in the UK using the neuroAD™ Therapy System. They have all demonstrated significant improvements in their cognitive function (with improvements in their Addenbrooke’s Cognitive Examination scores). These positive results are consistent with the numerous patients treated in Europe, Asia and the USA.

"We are happy to introduce our system to the London market, to allow Alzheimer patients residing in this city to have access to the neuroAD™ technology,” said Eyal Baror, CEO of Neuronix Ltd. “With the new installation, our London Center joins other successful installations in other European and Asian regions.

"Alzheimer's disease is one of the greatest challenges facing practitioners due to an aging population that is living longer; our patients and their families are looking for new treatments that can improve the symptoms of this disease," said Dr. Wayne Kampers, Consultant Psychiatrist and Medical Director of the London Neuronix Center. "I am encouraged with the published data on the neuroAD™ Therapy System, and it has significantly helped those patients I have treated. With the completion of treatment of the first group of patients, I have personally witnessed the clinical and cognitive improvement in this group.”

“My confidence is back, and I’m much more sociable, less aggressive and irritable. I’m quite excited that I have my memory back. I’d absolutely recommend this treatment without hesitation,” said the first patient treated who travelled from South Africa in order to undergo the treatment,“It’s made me want to live, it’s changed my life.”

About Neuronix Ltd and the neuroAD™ Therapy System

Neuronix Ltd (neuronixmedical.com) Is a privately-owned company, with headquarters in Yoqneam, Israel, and subsidiaries in the USA and UK. Neuronix has developed and manufactures a novel breakthrough medical-device technology for treatment of established mild to moderate Alzheimer's disease.
Alzheimer's disease is considered one of the greatest challenges to treat with limited available drugs offering only partial clinical benefit, frequently limited by side effects. This disease affects more than 5M people in the United States alone, and an estimated over 30M across the world.
The neuroAD Therapy System is a patent-protected, non-invasive medical device, uniquely combining transcranial magnetic stimulation (TMS) with cognitive training, to concurrently target brain regions affected by Alzheimer's disease. This dual-stimulation is designed to improve cognitive performance of patients, following an intervention protocol, which lasts for six weeks, five days per week, with one hour-long session per day.

The neuroAD™ Therapy System is approved for use in Europe (CE Marked 0482), as well as in other regions.
It is commercially available in established Alzheimer's centers in Europe and Asia. In the UK, the System is now available at The Neuronix Center, 29, Weymouth Street, London, W1G 7DB and Phoenix Health Mental Services, Wooburn Green, Buckinghamshire.

In the United States, the neuroAD™ Therapy System is an experimental device and is not yet available for sale.

Eyal Baror, CEO
T: +972 54 493 2572 - E: patientinfo[.]neuronixmedical.com.

The Neuronix Center
29 Weymouth St London W1G 7DB
T: +44(0)20 3906 8378

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Neuronix Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Neuronix Ltd Announces the First Group of Mild to Moderate Alzheimer Patients to be Successfully Treated by The NeuroAD™ Therapy System

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Alexandra Sore - AlexPublicity.co.uk for Neuronix 
+44(0)79 8399 8622 hello[.]alsmarketing.co.uk
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Neuronix Ltd securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Neuronix Ltd / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Cutting-Edge micro-CT Imaging Research Shines New Light on Mooted SARS-CoV-2 Treatments
Bruker Launches Revolutionary High-Speed AFM System for Single-Molecule Applications
Bruker Launches Second-Generation FluoroType® SARS-CoV-2 plus PCR Test for Detection of SARS-CoV-2 Viral Infections in Europe
SCHOTT Launches New VisiLED UV Ring Light for Stereo Microscopy
Citizen Care Pod Corp. Collaborates with WZMH Architects, PCL Construction, Insight Enterprises and Microsoft to Launch A Custom Mobile Testing Unit
American Regent Inc. Selects Sparta Systems’ TrackWise Digital QMS to Seamlessly Connect Quality Across Manufacturing, Clinical and Supplier Network
Frost & Sullivan Analyzes the Future of Adhesion Prevention Products in the US and EU5
FORA Auto Temperature Measurement Station Provides Protection During COVID-19
TPEs Introduces A Range of TPE-compounds for Direct Contact with Blood and Body Fluid Applications in the Medical Sector
Safran and Segula Technologies Continue to Support the Fight Against Covid-19 by Adapting Decathlon’s Easybreath Subea Mask for Use in Hospitals

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  JobsWare.com

Visit  Limelon Advertising, Co.







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today